Filsuvez Medical Drug Criteria
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
Medical policy outlining prior authorization criteria, coding, and coverage rules for Filsuvez topical gel for treatment of partial-thickness wounds in patients with inherited epidermolysis bullosa for Blue Cross Blue Shield of Kansas members.
Removed additional testing requirements of IFM or TEM and updated diagnosis and genetic testing requirements.
Added disallowance requirement for combination therapy on the same wound of gene therapy product.
Moved/indented FDA age requirements to bypass continuation of therapy and standardized formatting.
Added HCPCS code J3490 to coding section.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.